Please visit answersincme.com/BTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses recent clinical data in dual immunotherapy combinations for non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Discuss the most recent clinical data informing the efficacy and safety of chemotherapeutic regimens, including dual immunotherapy and chemotherapy combination regimens, in advanced non–small-cell lung cancer (NSCLC); Identify strategies for tailoring dual immunotherapy and chemotherapy combination regimens for individualized frontline treatment of advanced NSCLC; and Outline practical approaches to improve quality of life in patients with advanced NSCLC on frontline dual immunotherapy and chemotherapy combination regimens.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related